A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
Recruiting · NCT06696326 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The main objective of this research is to develop and evaluate new PET imaging agents with high sensitivity and specificity for prostate cancer and other aggressive tumors. Specifically, the research focuses on improving upon existing prostate cancer imaging methods, such as PSA tests and PSMA PET/CT, which have limitations in sensitivity, specificity, and the ability to provide comprehensive tumor information，and aims to create a novel PET probe targeting Trop2, an antigen highly expressed in multiple cancer types, to enable in vivo, whole-tumor assessment. This would support early diagnosis, more precise staging, and effective monitoring of cancer therapy.
Who can take part
Inclusion criteria
- Patients with initial diagnosis of prostate cancer, or patients with biochemical recurrence after radical prostatectomy or radical radiotherapy.
- Estimated survival time \>3 months, as determined by a physician.
- Willing to sign the informed consent form voluntarily and able to comply with the study protocol.
Exclusion criteria
- Individuals unable to tolerate intravenous administration (e.g., history of needle or blood phobia).
- Patients deemed unsuitable by researchers or unable to complete PET or other imaging examinations due to specific conditions, such as claustrophobia or radiophobia.
- Individuals with occupational exposure to radiation.
- Patients with severe diseases affecting the heart, kidneys, lungs, vascular, neurological, or mental systems, immune deficiency disorders, or hepatitis/cirrhosis.
- Other conditions that researchers deem unsuitable for participation in the study.
Where it is running
1 location listed.
- The First Affiliated Hospital of Xiamen University - Xiamen, Fujian, China